Business Description
Terns Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US8808811074
Share Class Description:
STU:430: Ordinary SharesDescription
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 285.65 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4 | |||||
| 3-Year EPS without NRI Growth Rate | 10.4 | |||||
| 3-Year FCF Growth Rate | 10.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -6.03 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.02 | |||||
| 9-Day RSI | 34.75 | |||||
| 14-Day RSI | 38.98 | |||||
| 6-1 Month Momentum % | -20.86 | |||||
| 12-1 Month Momentum % | -3.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 32.99 | |||||
| Quick Ratio | 32.99 | |||||
| Cash Ratio | 32.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -41.6 | |||||
| Shareholder Yield % | 0.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -33.02 | |||||
| ROA % | -31.54 | |||||
| ROIC % | -1748.24 | |||||
| ROC (Joel Greenblatt) % | -9432.08 | |||||
| ROCE % | -37.28 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.37 | |||||
| Price-to-Tangible-Book | 1.37 | |||||
| EV-to-EBIT | -1.28 | |||||
| EV-to-Forward-EBIT | -1.19 | |||||
| EV-to-EBITDA | -1.29 | |||||
| EV-to-Forward-EBITDA | -1.19 | |||||
| EV-to-FCF | -1.71 | |||||
| Price-to-Net-Current-Asset-Value | 1.38 | |||||
| Price-to-Net-Cash | 1.39 | |||||
| Earnings Yield (Greenblatt) % | -78.13 | |||||
| FCF Yield % | -14.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Terns Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.082 | ||
| Beta | -1.3 | ||
| Volatility % | 89.72 | ||
| 14-Day RSI | 38.98 | ||
| 14-Day ATR (€) | 0.217761 | ||
| 20-Day SMA (€) | 6.0475 | ||
| 12-1 Month Momentum % | -3.17 | ||
| 52-Week Range (€) | 4.12 - 10 | ||
| Shares Outstanding (Mil) | 84.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Terns Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Terns Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Terns Pharmaceuticals Inc Frequently Asked Questions
What is Terns Pharmaceuticals Inc(STU:430)'s stock price today?
The current price of STU:430 is €5.75. The 52 week high of STU:430 is €10.00 and 52 week low is €4.12.
When is next earnings date of Terns Pharmaceuticals Inc(STU:430)?
The next earnings date of Terns Pharmaceuticals Inc(STU:430) is 2025-03-14 Est..
Does Terns Pharmaceuticals Inc(STU:430) pay dividends? If so, how much?
Terns Pharmaceuticals Inc(STU:430) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers